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The emergence of leukemia following gene transfer to 
restore common cytokine receptor γ chain (γC) func-
tion in X-linked severe combined immunodeficiency 
(SCID-X1) has raised important questions with respect to 
gene therapy safety. To explore the risk factors involved, 
we tested the oncogenic potential of human γC in new 
strains of transgenic mice expressing the gene under the 
control of the CD2 promoter and locus control region 
(LCR). These mice demonstrated mildly perturbed T-cell 
development, with an increased proportion of thymic 
CD8 cells, but showed no predisposition to tumor devel-
opment even on highly tumor prone backgrounds or 
after γ-retrovirus infection. The human CD2-γC trans-
gene rescued T and B-cell development in γC−/− mice 
but with an age-related delay, mimicking postnatal 
reconstitution in SCID-X1 gene therapy subjects. How-
ever, we noted that γC−/− mice are acutely susceptible 
to murine leukemia virus (MLV) leukemogenesis, and 
that this trait was not corrected by the γC transgene. We 
conclude that the SCID-X1 phenotype can be corrected 
safely by stable ectopic expression of γC and that the 
transgene is not significantly oncogenic when expressed 
in this context. However, an underlying predisposi-
tion conferred by the SCID-X1 background appears to 
 collaborate with insertional mutagenesis to increase the 
risk of tumor development.
Received 10 December 2008; accepted 3 March 2009; published online 
31 March 2009. doi:10.1038/mt.2009.59
IntroductIon
Although correction of X-linked severe combined immunodefi-
ciency (SCID-X1) was an early success for the gene therapy field,1 
this advance was compromised by the development of leukemia 
(T-lineage acute lymphoblastic leukemia) in trial subjects, with 
5 of 19 patients from two similar trials developing this complica-
tion to date.2–4 As a matter of further concern, the therapeutic vec-
tor was implicated as a causal agent in these leukemias and in four 
cases was found to have integrated into the Lim-only  protein 2 
(LMO2) gene, a known target for oncogenic activation in human 
T-lineage acute lymphoblastic leukemia.5
This outcome was not anticipated as it was assumed that a 
single hit of vector integration would be insufficient to initiate 
oncogenic transformation of a normal cell.6 However, it is con-
ceivable that factors specific to the trial led to increased leuke-
mia susceptibility. One of the features that distinguishes gene 
therapy for SCID-X1 from most other trials is the marked selec-
tive advantage conferred on corrected cells.7 It has also been sug-
gested that the therapeutic gene itself has oncogenic properties, 
particularly when expression is controlled by heterologous retro-
viral regulatory elements rather than endogenous sequences. The 
common cytokine receptor γ chain (γC) is a component of recep-
tors for multiple cytokines, including IL-2, 4, 7, 9, 15, and 21.8 
Increased responsiveness to any of these cytokines is likely to have 
biological effects which may include aberrant proliferation and 
 differentiation.9 Although no neoplastic disease was observed in 
preclinical trials of vectors expressing γC in mice,10 these studies 
were of short duration and did not test the effects of combina-
tion with other leukemogenic factors. Circumstantial evidence in 
support of the cooperating oncogene hypothesis was provided by 
the finding of insertions near murine γC as well as LMO2 in a 
case of murine T-cell leukemia.11 However, there are conflicting 
findings on the leukemogenicity of vector-driven expression of γC 
in mouse models. A recent study reported that, γC null (γC−/−)
mice reconstituted with a lentivirus vector expressing murine γC 
at high level succumbed to lymphomas at a significant rate.12 In 
contrast, another study reported that vector-driven LMO2 expres-
sion perturbed hematopoietic development of human CD34 cells 
whereas γC had no obvious effects.13
For this study, we derived new lines of mice expressing high 
levels of human γC under the control of the human CD2 promoter 
and locus control region (LCR). The CD2 element was chosen for 
its reliability and potency in driving transgene expression in the 
T-cell compartment, which has revealed the oncogenic potential of 
a diverse range of genes.14–20 Transgenic systems provide a power-
ful approach to testing the oncogenic potential of weak oncogenes, 
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which can often be revealed in combination with a more powerful 
initiating oncogene or an inactive tumor suppressor gene in the 
germline.18,21–23 Such systems also afford the opportunity to test for 
synergy with long terminal repeat-driven insertional mutagenesis 
by Moloney murine leukemia virus (MoMLV) following neona-
tal infection.23,24 MoMLV is a potent inducer of T-cell lymphoma, 
with tissue-specificity mapping principally to its long terminal 
repeat enhancer elements.25
We followed γC transgenic mice closely for signs of develop-
mental abnormalities, for predisposition to spontaneous tumors, 
and for evidence that the transgene can accelerate tumor devel-
opment in combination with other oncogenic factors. Although 
the transgene can reconstitute lymphoid development on a γC−/− 
background, we find no evidence of an increase in tumor develop-
ment. However, infection of γC−/− mice reveals that these animals 
are highly susceptible to murine leukemia virus (MLV) leukemo-
genesis, and this underlying susceptibility remains uncorrected 
by the γC transgene. The significance of these observations for 
SCID-X1 therapy is discussed.
results
Generation of transgenic lines ectopically  
expressing human γc in the t-cell compartment
To study the effects of ectopic γC expression on hematopoietic 
development and tumor susceptibility, we generated a construct 
containing an LCR from the human CD2 locus linked 5′ to the 
coding region to generate CD2-hγC (Figure 1a). This construct 
was used to generate two transgenic lines, gCA and gCB, ectopi-
cally expressing human γC. Presence of the transgene was con-
firmed by both Southern blot and PCR analysis in positive mice 
(data not shown). Flow cytometry was carried out to confirm 
the expression of human γC in T cells present in thymocytes 
and splenocytes from transgenic mice using antihuman CD132 
(Figure 1b). Reverse transcriptase-PCR specific to the human 
transgene was also used to verify expression of γC transcripts in 
the expected tissue compartments (Figure 1c).
cd2-hγc mice show a mild perturbation  
of t-cell development but no predisposition  
to spontaneous tumors
As the CD2 LCR directs expression mainly to the T-cell 
compartment,14,26 thymic development in the transgenic mice was 
examined in detail. Although there was no evidence for changes 
in total thymocyte number or gross phenotypic alteration, cell 
surface marker expression analysis of thymocytes by flow cytom-
etry revealed a mild perturbation in the CD4:CD8 T-cell ratio. 
Specifically, transgenic mice from the higher expressing line (gCB) 
had significantly lower levels of CD4 single positive cells and 
higher levels of CD8 single positive cells than their nontransgenic 
counterparts (Table 1 and Figure 2a). A similar trend, though less 
pronounced, was seen in the gCA line. To establish the nature of 
the expanded CD8+ population we examined expression of func-
tional markers including CD24 (heat stable antigen) and T-cell 
receptor β. Transgenic CD8+ thymocytes displayed lower expres-
sion of heat stable antigen when compared to nontransgenic con-
trols consistent with a shift in the maturity of the T-cell population 
(Figure 2b), whereas expression of T-cell receptor β was also con-
sistent with a more mature phenotype (Figure 2c). There was no 
difference between transgenics and littermate controls in the level 
of heat stable antigen by flow cytometry when gated on CD4+ 
cells (data not shown).
A cohort of transgenic animals was maintained for a period of 
2 years to determine whether expression of human γC in the T-cell 
compartment predisposed to the development of lymphoma. 
Transgenic lines gCA (n = 31) and gCB (n = 35) remained tumor 
free up to 18 months of age. All of the littermate controls (n = 48) 
remained tumor free over the observation period.
lack of tumor acceleration by human γc in mice 
infected with MoMlV or genetically predisposed  
to t-cell lymphoma
In transgenic mouse systems, the action of weak oncogenes 
that are inefficient initiators of tumor development can often be 
revealed by neonatal infection with MLVs. The rationale for this 
observation is that these viruses are potent insertional mutagens 
that insert essentially randomly and cause gene activation or inac-
tivation events that act in concert with the weak initiator delivered 
through the germline. The rapid onset of tumors in transgenic 
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Figure 1 Generation and analysis of animals transgenic for human 
γc. (a) Plasmid construct illustrating the CD2 promoter driven human γC 
transgene (Sa – Sal1, Xb – XbaI, Pc – PciI, Mu – MluI). (b) Expression of 
the human γC from the CD2 promoter was confirmed in the transgenic 
mice by flow cytometry analysis of human γC surface expression in thy-
mocytes from a CD2-hγC transgenic and control mouse. Expression of 
mouse γC is also shown for comparison. (c) RT-PCR in tissue from spleen 
(Spl), kidney (Kid), and thymus (Thy) from either a CD2-hγC transgenic 
animal (lanes indicated by +) or a nontransgenic littermate (lanes indi-
cated by −). Control RNA isolated from PG-13 cells without (ctrl−) or 
with human γC vector (ctrl+).
table 1 Average population values for t-cell markers in both control 
and transgenic mice
% cd4+ %dP %dn %cd8+ cd4:cd8
Control  
(n = 22)
21.8 (±5.5)* 59.0 (±9.2) 9.7 (±2.5) 9.4 (±3.4)* 2.4*
CD2-hγC  
(n = 15)
15.7 (±4.0)* 61.7 (±7.7) 8.2 (±2.3) 14.3 (±4.8)* 1.2*
Mean (±s.d.).*P < 0.03.
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compared to wild-type control mice is an indication of this type 
of synergistic relationship.27,28 To test the oncogenic potential of 
ectopic human γC by this criterion, transgenic mice and littermate 
controls were infected with MoMLV, a potent inducer of T-cell 
lymphomas. However, no significant acceleration of tumor onset 
in the presence of human γC was observed in either the gCA or 
gCB transgenic lines (Figure 3a). A slight trend toward accelera-
tion in the gCB line was not sustained as the cohort aged.
As a further stringent test of oncogenic potential, the gCB 
transgenic line was crossed with a variety of lymphoma-prone 
models. The human γC transgene was first crossed onto a 
p53−/−  background, which collaborates strongly with a range of 
oncogenes.23,29 From a cohort of 17 transgene positive, p53 null 
mice (CD2-hγCxp53−/−), 15 developed tumors with an average 
latency of 178 days. For the transgene negative littermate controls 
(p53−/−) 14 out of 15 animals succumbed with an average latency 
187 days (Figure 3b), showing no significant acceleration of 
tumor onset by the γC transgene on a strain-matched background. 
Animals null for the p53 gene succumb to a variety of tumor types 
of lymphoid and nonlymphoid origin,30 thus a further test of onco-
gene cooperation can be observed from the tumor spectrum. The 
presence of the human γC transgene did not alter the tumor spec-
trum of the p53−/− animals with similar numbers of lymphoma 
and solid tissue tumors observed irrespective of the transgene sta-
tus. This contrasts with other oncogene models where a shift in the 
tumor phenotype to lymphoid tumors is noted.23,29 Previously we 
have monitored the incidence and latency of lymphoma develop-
ment in p53 heterozygous animals carrying the Myc transgene.31 
The presence of the gCB transgene on this strain-matched back-
ground (n = 21) did not increase the rate of tumor development 
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Figure 2 thymus explanted from transgenic and control animals were analyzed for cell surface marker expression to characterize the cell 
phenotype. (a) Perturbation of the CD4:CD8 T-cell ratio was observed in the total cell population for the CD2-hγC transgenic mice (1:1) (n = 15) 
compared with (2:1) in littermate controls (n = 22). Data representative of a transgenic profile and littermate control is shown. Average population 
values are indicated in Table 1. (b) Transgenic CD8+ thymocytes displayed lower expression of HSA (CD24) when compared to nontransgenic con-
trols, illustrating a more mature T-cell phenotype. These histograms were gated on the CD8SP population (quadrant B4 in a). (c) Total thymocyte 
populations were stained for HSA and TCRβ to show that CD2-hγC transgenic mice appear to have an increased percentage of mature lymphoid cells 
as represented by TCRβ+HSA−. Average mean ± s.d. values are given.
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Figure 3 lack of tumor acceleration by human γc in mice. (a) Tumor free survival in two CD2-hγC transgenic lines gCA (n = 45) and gCB (n = 19), 
and controls (n = 41) after infection with MoMLV. Animals were on a C57/B16xCBA background where wild-type controls were strain and generation 
matched littermates. In animals succumbing to neoplastic disease there was no significant difference in the rates of lymphoma development between 
either transgenic line or the controls (gCA versus control, P = 0.32; gCB versus control, P = 0.51). Neither was there a significant difference between 
the two transgenic lines (gCA versus gCB, P = 0.15). (b) Tumor free survival of CD2-hγC/p53−/− (n = 17) mice was indistinguishable (P = 0.63) to 
that observed with p53−/− littermates without the human γC transgene (n = 15).
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(data not shown) confirming that the CD2-hγC transgene does not 
predispose to lymphoid malignancy.
the cd2-hγc transgene reconstitutes t and  
B-cell development on a γc null background
Human patients with γC deficiency lack T cells, and have dysfunc-
tional B cells. By comparison, mice lacking a functional γC gene 
display thymic hypoplasia and have reduced numbers of periph-
eral T cells. B cells are also decreased in number and are dysfunc-
tional.32 We wished to test the potential of the CD2-hγC transgene 
to rescue lymphoid development and function in γC−/− mice, 
both to confirm its functionality and to explore the potential of 
this system to model for the clinical setting in SCID-X1 patients 
where γC expression has been partially restored.
Human γC (gCB) transgenic mice were backcrossed three 
generations to derive offspring carrying the γC transgene on a 
γC−/− background. Analysis of the size and cellularity of the thy-
mus in transgenic and control γC−/− mice revealed that the mice 
positive for the transgene had a significantly higher thymus to 
body weight ratio than the null animals (Figure 4a) and increased 
thymic cellularity (Figure 4b) although neither were fully restored 
to wild-type levels in the reconstituted animals. Western blot 
analysis confirmed the expression of human γC (Figure 4c). To 
analyze functionality, we examined the phosphorylation status of 
STAT5 after mitogenic stimulation. STAT5 proteins A and B are 
phosphorylated via the Janus kinase protein pathway as a result 
of activation in response to cytokines including IL-2, 3, 5, and 7 
that signal via γC receptor complexes. The phosphorylation sta-
tus of STAT5 has been used previously as an indicator of restored 
lymphopoiesis after reconstitution with human γC 33 and confirms 
here the functionality of CD2-driven human γC (Figure 4c).
Analysis of cohorts of CD2-hγCx murine γC−/− mice showed 
that development of mature lymphoid populations was delayed 
compared to wild-type counterparts. The vestigial thymus of 
γC−/− mice displays an aberrant population of CD4+ T-cells, 
and a reduced percentage of double positive CD4/CD8 cells 
(Figure 5a). At 8 weeks, the transgenic mice showed partial cor-
rection of this imbalance, whereas at 16 weeks marker expression 
was essentially indistinguishable from wild-type. This finding was 
also reflected in the spleen, where CD8 T-cell populations were 
not evident until 16 weeks (not shown). B-cell development in the 
spleen appeared to recover later than thymic T cells. At 8 weeks of 
age splenic populations were essentially identical to γC−/− mice, 
but by 16 weeks had recovered in most mice to wild-type levels, as 
revealed by staining for surface immunoglobulin M and CD45R 
(Figure 5b). The marked splenomegaly seen in γC−/− mice was 
also reduced with expression of the transgene (not shown).
The basis of B-cell reconstitution was of interest as the CD2 
promoter/LCR elements were expected to direct transgene expres-
sion to the T-cell compartment. However, CD2 promoter function 
has also been detected in B-cells although its activity appears to 
decline with maturation.26 To test for sustained expression of the 
transgene we fractionated CD45R+ cells from the spleens of recon-
stituted mice and carried out western blot analysis. Abundant 
transgene expression was detected in CD45R+ as well as CD45R− 
cell populations (Figure 5c).
transgenic reconstituted mice display ameliorated 
disease but no spontaneous lymphoma development
Abnormalities displayed by γC−/− mice due to immune dysregu-
lation include colitis 32,34 and this problem was often manifested in 
our cohort as rectal prolapse, requiring early termination. It was 
notable that none of the transgenic mice displayed this condition 
compared with 16% of γC−/− controls (P < 0.05). This disease 
amelioration was reflected in a marked survival advantage for 
transgenic mice over their γC−/− littermates. Some aspects of the 
γC−/− phenotype continued to be manifested in the transgenic 
mice, albeit with less acute presentation. However, careful patho-
logical examination of 19 such mice sacrificed between 66 and 318 
days of age revealed no evidence of neoplastic disease.
γc−/− mice display high susceptibility  
to MlV-induced lymphoma which  
is not altered by the cd2-hγc transgene
As a further test of the intrinsic oncogenicity of ectopic γC expres-
sion, we examined the effect of the transgene on susceptibility to 
MLV leukemogenesis on a γC−/− background. A striking obser-
vation is that γC−/− mice are unusually susceptible to MLV leu-
kemogenesis with a rate of onset of tumors substantially faster 
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Figure 4 restoration of γc-null lymphoid compartments was deter-
mined by organ weight and cell number at necropsy. The ratio of 
thymus to body weight (a) and thymic cellularity (b) is given for CD2-hγC 
reconstituted transgenic mice (where cohort numbers for (a) and (b) 
respectively are n = 18 & n = 3) compared to the strain matched γC−/− 
(n = 15 & n = 7) and wild-type (n = 12 & n = 5) controls. *P < 0.05, 
**P < 0.01. (c) Western blots of thymus extracted from two individual 
transgenic and control animals showing expression of the transgene 
only in the CD2-hγC animals. Human γC was functional in the recon-
stituted animals as confirmed by phosphorylation of STAT5A/B. Loading 
was controlled with β-actin.
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(P < 0.01) than strain matched wild-type controls (Figure 6). 
The copy number of integrated MLV was similar in both null 
and wild-type backgrounds (average ~9 copies/tumor) suggest-
ing that this susceptibility is not directly accounted for by an 
increased virus load. Nevertheless, the rate of onset of tumors in 
CD2-hγC reconstituted γC−/− mice was unchanged compared 
to γC−/− littermates, showing that the γC transgene neither 
accentuated nor diminished the risk of MLV leukemogenesis 
(Figure 6).
dIscussIon
In this study, we generated new lines of mice ectopically express-
ing human γC and examined the effects of the transgene on 
hematopoietic development and susceptibility to tumor develop-
ment. Although the transgene induced a mild perturbation in thy-
mic development as revealed by an expansion of mature CD8SP 
cells, we found no evidence of spontaneous tumor development. 
Moreover, no significant acceleration of tumor onset was seen in 
mice where we combined the γC transgene with a strong genetic 
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Figure 5 (a) Delayed restoration of T-cell populations in the thymus of γC−/− mice reconstituted with human γC. Examples of CD4/CD8 profiles are 
given for CD2-hγC+/mγC−/−, γC−/− and strain-matched wild-type (mγC+) at 8 weeks (top) and 16 weeks (bottom) of age. At 16 weeks, the average 
percentages ± s.d. for CD4SP were 16.6 ± 8.0, 27.0 ± 16.0 and 17.6 ± 6.8, and for CD4/8DP populations 73.7 ± 11.0, 45.9 ± 20.5 and 74.5 ± 8.8 for 
the wt (n = 5), null (n = 7) and transgenic (n = 6) animals, respectively. (b) Delayed restoration of the B-cell population in the spleens of γC−/− mice 
reconstituted with human γC. The panels show representative examples of viable splenocytes analyzed for immunoglobulin M and CD45R surface 
expression in three different hγC+/mγC−/− animals in addition to γC−/− (n = 5 at 8 weeks and n = 7 at 16 weeks) and strain-matched wild-type 
(mγC+, n = 5 at 8 weeks and n = 7 at 16 weeks) control mice. (c) Western blot analysis of human γC in sorted splenic B cells. Purified CD45R+ cells 
were isolated from CD2-hγC+/mγC−/− spleens (n = 4) and analyzed for γC expression. As the antibody crossreacts with murine γC, a positive signal 
was evident in wild-type mouse spleen, but not in the splenocytes of mγC−/− animals. β-Actin is shown to control for loading. The hγC+ control was 
the lysate from fibroblast cells (PG13) transfected with the γC vector.
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predisposition to lymphoma (Myc transgene or p53 null) or with 
neonatal infection by a highly lymphomagenic γ-retrovirus. We 
confirmed that the transgene was expressed and functional, and 
capable of driving reconstitution of the lymphoid compartment 
on a γC−/− background. Even in this context, the transgene did 
not cause a discernible change in predisposition to MLV-induced 
lymphoma development.
Our results raise further questions with regard to the role 
of the γC transgene in leukemias arising in children following 
SCID-X1 gene therapy. Another study suggested that the gene 
might be potently oncogenic, as lymphoma development was 
noted in γC−/− mice that had received a lentivirus vector express-
ing the γC gene.12 As noted elsewhere 35 this was a relatively small 
study where the role of insertional mutagenesis was not explored 
in depth. Although our results do not exclude the possibility that 
γC can contribute to oncogenesis when expressed at higher level 
or in a different cell compartment, they show that ectopic expres-
sion of the human γC gene at levels sufficient to correct the defect 
on a γC−/− background do not predispose to tumor development. 
This conclusion is also supported by the findings of a recent study 
which showed that LMO2, but not γC, could block T-cell develop-
ment when expressed from a retroviral vector in human CD34 
cells.13 Moreover, studies of the leukemia cells from SCID-X1 
patients suggested that γC was not expressed at elevated levels.36
The frequent occurrence of vector insertions at LMO2 in 
four out of five leukemias arising in SCID-X1 gene therapy sub-
jects indicates a remarkably strong selection for activation of this 
 proto-oncogene.36,37 A previous report suggested the possibility 
that γC and LMO2 might be acting as cooperating oncogenes in 
this context.11 This suggestion was based on the co-occurrence of 
retroviral integrations at both loci in a case of MLV-induced lym-
phoma, despite the rarity of insertions at each locus in a database 
of >3,000 tumor-derived MLV insertion sites. However, inspec-
tion of the current RTCGD database (http://rtcgd.abcc.ncifcrf.
gov/) reveals that the three recorded insertions close to the γC 
gene are actually located within the 5′ end of a neighboring gene, 
Med12, that encodes a transcriptional co-activator with a specific 
role in Wnt signaling.38 As this gene appears a plausible target 
on the basis of proviral location and orientation,27,39 the possibil-
ity has to be considered that the proximity of the cluster to γC is 
coincidental. The hypothesis that Med12 is the significant target 
for these insertions is also consistent with the observation that γC 
expression was not upregulated in the index tumor.11
Recent high throughput studies of vector insertion sites in 
the peripheral blood of healthy SCID-X1 patients monitored fol-
lowing gene therapy revealed a highly biased pattern, reflecting 
strong selection for a subset of target genes that are likely to posi-
tively affect cell growth.2,3 The emerging picture is that, although 
the human γC gene plays a facilitating role in allowing the target 
cell population to expand, it is primarily the insertional mutagenic 
potential of the vector that drives the process of neoplastic trans-
formation along with other genetic changes typical of T-lineage 
acute lymphoblastic leukemia, including Notch mutations, chro-
mosomal translocations and CDKN2A deletions.36,37
It is interesting to note that in the present study infection of 
γC−/− mice with MoMLV was found to drive T-cell lymphom-
agenesis even faster than in strain matched wild-type mice, in 
spite of the markedly smaller thymus on this background. The 
basis of this acute sensitivity is of interest with regard to pos-
sible parallels with SCID-X1 disease. Lack of antiviral immunity 
seems unlikely to be a major factor as neonatal mice are unable to 
mount a significant response to MLV. It is conceivable that tumor 
immune surveillance is impaired on the γC−/− background and 
that transgene-driven reconstitution is too slow to have a deci-
sive effect on the nascent tumor cells. It is interesting to compare 
our observations with those of a recent study which examined the 
development of leukemias in a mouse SCID-X1 model entailing 
vector-driven correction of the defect in an Arf null background.40 
The study identified a decisive role for vector insertional muta-
genesis but also reported an increased susceptibility when γC−/− 
donor cells were used instead of wild-type controls. The presence 
in γC−/− mice of an expanded immature T-cell population that is 
sensitive to transformation was offered as a potential explanation 
that would also be consistent with our findings.
In conclusion, this study demonstrates that controlled, stable 
expression at levels sufficient to correct the SCID-X1 deficit can 
be achieved without contributing to tumor predisposition. If 
problems arising from insertional mutagenesis can be controlled 
by improved vector design or delivery methods,41,42 it would 
appear that correction of this disease by gene therapy is likely 
to be achievable with an adequate margin of safety. However, 
the underlying susceptibility to leukemogenesis imposed by the 
γC−/− background confers a continuing risk specific to SCID-X1 
gene therapy that requires further investigation.
MAterIAls And Methods
Generation of CD2−hγC. The γC coding region was amplified by PCR from 
the MFG-γC vector (kindly provided by K. Parsley, ICH, London) using 
the Taq PCR Core kit according to the manufacturer’s instructions (Qiagen, 
West Sussex, UK) Primers (PciMFG: gcaagcgacatgttgaagcc; MluMFG: 
gatacgcgttcaggtttcaggc) were used for amplification and the resulting prod-
uct was cloned into pCR2.1 Topo (Invitrogen; Paisley, UK) and the presence 
of the γC insert confirmed. The γC coding region was digested with Pci1 
and MluI and subcloned into the multiple cloning region of the CD2 mini-
gene vector VA hCD2 (ref. 43) (a kind gift of D. Kioussis). The presence of 
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Figure 6 lymphoma-free survival of MoMlV infected cd2-hγc+/
mγc−/− (n = 40), mγc−/− (n = 11) and strain matched mγc+ mice 
(n = 20). The presence or absence of the CD2-hγC transgene had no sig-
nificant effect on lymphoma-free survival (P = 0.33), although mγC−/− 
were markedly more sensitive to virus-induced lymphoma than wild-type 
controls (P < 0.001).
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γC inserts was verified by double restriction digestion with KpnI and XbaI 
and the 5′ and 3′ ends of positive clones sequenced in order to determine 
the orientation of γC relative to the promoter. The CD2-hγC DNA was pre-
pared for microinjection by digestion with Kpn1 and Xba1, followed by 
gel purification using the Geneclean Turbo system (BIO 101; Q-BIOgene, 
Cambridge, UK) according to the manufacturer’s instructions.
Transgenic mice. The 14 kb CD2-hγC restriction fragment was micro-
injected into C57/B16xCBA/Ca F2 fertilized eggs according to standard 
protocols44 to generate the CD2−hγC transgenic mice. CD2-MYC-ER 
transgenic,31 p53 knockout 30 and mice with a null mutation in γC (γC−/−)45 
have been described previously. Mice were housed in conventional or indi-
vidual ventilated cages. Neonates were infected within 24 hours of birth 
with ~105 infectious units of MoMLV.28 Animals were routinely monitored 
and sacrificed when showing signs of ill health. To control for mouse strain 
and generation all survival analyses were carried out with littermate con-
trols, with the exception of the CD2-hγC/Myc/p53+/− experiment which 
was strain matched (C57/B16xCBA/Ca). All animal work was undertaken 
in line with the UK Animals (Scientific Procedures) Act of 1986.
Genotyping and detection by PCR. Human γC transgenic mice were iden-
tified by Southern blot hybridization or PCR analysis on DNA extracted 
after tissue biopsy. Southern blotting was carried out using a probe 
designed to human γC, nucleotides 345-604 (accession number: D11086). 
20 µg of DNA was digested with BglII and NcoI. Hybridization was carried 
out and filters washed with 2 × SSC, 0.1% SDS.
PCR for human γC was carried out in a 50 µl reaction with 20 pmol 
of primers 5′-CAG CTC TGA GCC CCA GCC T-3′ and 5′-CTT TTG 
GGG GAA TCT CAC TGA CGA-3′ using Taq PCR core kit (Qiagen). 
The copy number of the γC transgene was estimated by Southern blot 
and densitometry, indicating that the gCA and gCB lines carry two and 
five copies of transgene, respectively. Transcript levels were estimated by 
real-time PCR.
Cell isolation and immunophenotype analysis. Lymphoid/tumor tissue 
was disaggregated in RPMI (Invitrogen, Paisley, UK) containing 10% FCS, 
2 mmol/l glutamine, 50 µmol/l β-mercaptoethanol, and penicillin/strepto-
mycin by mashing through a 70-µm cell strainer. Ficoll-Paque (Pharmacia, 
Kent, UK) separation of viable lymphocytes at 3,000 rpm for 10 minutes 
was used in all cases. B-cell isolation (to ~85% purity) was carried out on 
splenocytes using magnetic separation techniques with CD45R micro-
beads as per manufacturers’ instructions (Miltenyi Biotech, Surrey, UK).
Cells (~2 × 106) were washed in cold PBS containing 0.1% bovine serum 
albumin and 0.01% sodium azide and directly labeled with a combination 
of rat antimouse monoclonal antibodies: Fluorescein (FITC)-conjugated 
anti-CD8 (Serotec, Oxford, UK); phycoerythrin (PE)-conjugated anti-
CD4, FITC-conjugated anti-heat stable antigen, CyChrome-conjugated 
T-cell receptor β-chain, PE-conjugated anti-human CD132, PE-conjugated 
anti-CD43, Cy5-conjugated anti-mouse CD3 (BD PharMingen, Oxford, 
UK), Tri-color anti-CD19, biotin-conjugated anti-immunoglobulin M and 
PE-conjugated anti-CD45R (Caltag Medsystems, Buckingham, UK), FITC-
conjugated anti-DX5 (Miltenyi Biotech, UK). Cells were washed three times 
in cold PBS/bovine serum albumin/sodium azide and resuspended in 500 µl 
of PBS/bovine serum albumin/sodium azide. Analysis was carried out on a 
Beckman Coulter Epics XL using Expo32 software.
Western blot analysis. Whole-cell extracts were prepared by washing 
cells in cold PBS followed by lysis in buffer (20 mmol/l HEPES, 5 mmol/l 
EDTA, 10 mmol/l EGTA, 5 mmol/l NaF, 10% glycerol, 1 mmol/l DTT 
containing 0.4 mol/l KCl, 0.4% Triton X-100, 0.1 µg/ml okadiac acid, and 
protease inhibitors, 5 µg/ml leupeptin, 5 µg/ml aprotinin, 5 µg/ml pepsta-
tin A, 1 mmol/l benzamidine, 50 µg/ml phenylmethylsulfonyl fluoride). In 
all, 20 µg of protein extract were resolved on 12% NuPAGE Novex Bis-Tris 
gels (Invitrogen) and transferred to Hybond-ECL nitrocellulose mem-
branes (Amersham, Buckinghamshire, UK). Membranes were probed 
with antibodies to γC (no. AF284; R&D Systems, Oxon, UK), phospho-
rylated STAT5A/B (no. 06-588; Upstate, Milton Keynes, UK), and β-actin 
(Santa Cruz Biotechnology, Santa Cruz, CA). For activation of STAT5A/B 
cells were stimulated for 48 hours with human IL-2 (0.06 µg/ml; Peprotech, 
London, UK) and con-A (2.5 µg/ml; Sigma, Dorset, UK).
Histology of tumor tissue. Tissues were fixed in 10% neutral buffered 
formalin, dehydrated through graded alcohol solutions and embedded in 
paraffin wax. Histological sections (3–5 mm thick) were stained with hae-
matoxylin and eosin.
Statistical methods. All data are expressed as mean ± s.d. Data, including 
survival curves, were analyzed for significance using the Student’s t-test 
(two-tailed). Student’s t-test was deemed appropriate for survival analysis 
as the data met normal distribution criteria.
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